S. Ramesh, M. Guerrero, and M. Narobe
European Pharmaceutical Review. Volume 30, Issue 03
Abstract:
This whitepaper explores the use of the CIM® SO3 0.2 mL Monolithic 96-well Plate for optimizing rAAV upstream production. Bioprocess experts from Sartorius BIA Separations and BridgeBio Gene Therapy illustrate an approach with potential to expedite AAV upstream analytics and lower overall process development costs. The study highlights the plate’s role in purifying crude rAAV lysates efficiently, enabling high-throughput purification of small-scale bioreactor harvests. Achievements include ~90% capsid recovery for AAV9 and ~60% for AAV5, demonstrating favorable binding profiles and cost-effective purification compared to standard methods. The platform supports rapid, small-scale processing with broad assay compatibility, offering a robust alternative to affinity purification for early-stage rAAV development.
